Azienda Ospedaliero-Universitaria Careggi

Early Versus Late Biliary Leakage After Hepatic Resection: Incidence, Risk Profiles, and Clinical Impact of Diagnostic Timing

Background/Objectives: Post-hepatectomy biliary leakage (BL) remains a major source of postoperative morbidity. While traditional risk models treat BL as a single clinical entity, its chronological presentation follows distinct patterns that raise the hypothesis of distinct under...

Toward harmonized reporting of Alzheimer’s disease biomarkers in clinical practice

Abstract Cerebrospinal fluid biomarkers, and more recently blood-based biomarkers, are playing a pivotal role in reshaping the clinical management of neurodegenerative diseases, supporting early detection, biological diagnosis, patient stratification, prognostic assessment, thera...

Transcriptomic profile and endothelial changes during differentiation syndrome in acute promyelocytic leukemia

Abstract Acute promyelocytic leukemia (APL) is curable with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), but differentiation syndrome (DS) remains a potentially life-threatening complication, with poorly understood pathogenesis. We investigated clinical, molecular a...

International Society of Urological Pathology Multidisciplinary Expert Consultation Conference on Evaluation of Treatment Effects in Prostate and Bladder Cancer

Treatment effects in the urinary bladder are variable and range from localized post-transurethral resection changes to widespread systemic therapy effects. The International Society of Urological Pathology (ISUP) organized a consensus meeting in Vienna, Austria, in September 2025...

Combined Botulinum Toxin Type A and Hyaluronic Acid Versus Exclusive Hyaluronic Acid Injections: A Potential Nonsurgical Alternative for Chin Augmentation

Nonsurgical chin augmentation with hyaluronic acid (HA) fillers is a widely used technique in aesthetic medicine. However, outcomes may be influenced by hyperactivity of the mentalis muscle, which may lead to reduced longevity. Botulinum toxin type A (BoNT-A) may improve filler i...

Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy

Importance: Gene-silencing therapies reduce hepatic transthyretin (TTR) production and have been evaluated in phase 3 trials in TTR amyloid cardiomyopathy (ATTR-CM). However, differences in trial design and background therapies have limited assessment of the overall treatment eff...

Cancer in systemic sclerosis: clinical associations and prognostic impact from the EUSTAR registry

BACKGROUND: Cancer represents a major cause of mortality in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti-RNA polymerase III (POLR3)-positive disease, needing further exploration. METHODS: We performed a nested...

A survey among geriatricians on geriatric oncology and geriatric surgical oncology models in Europe

Abstract Purpose To provide an up-to-date overview of geriatricians’ involvement in oncological and onco-surgical care for older adults across Europe. Methods An anonymous 35-item online survey was distributed via (inter)national societies between 10 April and 23 May 2025. The re...

Development and Internal Validation of a Clinical Risk Score for Hypovitaminosis D in Italian Adults Aged ≥50 Years Attending Osteoporosis and Metabolic Bone Disease Centers

Background/Objectives: Hypovitaminosis-D is a highly prevalent condition worldwide, associated with adverse skeletal and extra-skeletal outcomes. Increasing demand for serum 25-hydroxyvitamin D (25(OH)D) testing points toward the need for simple tools to identify individuals at r...

Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

Baseline IPSS-M risk, response to hypomethylating agent (HMA) therapy, and receipt of allogeneic stem cell transplant (allo-HCT) have all been individually shown to impact overall survival (OS) in patients with myelodysplastic syndromes (MDS). However, the prognostic impact of re...

Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

Evidence to guide the treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with...

Decoding the causes of ischemic stroke despite ongoing oral anticoagulation and their clinical impact: the ASPERA-R study

BACKGROUND: Oral anticoagulants (OACs), including vitamin K antagonists and direct OACs, reduce stroke risk in atrial fibrillation (AF), yet breakthrough ischemic stroke still occurs in 1-2% of patients annually despite adequate therapy. The mechanisms underlying these events rem...

Multidisciplinary Delphi consensus-based recommendations on the use of image-guided radiotherapy for upper gastrointestinal tumours: an AIRO–AITRO–AIFM study

Abstract Objectives Upper gastrointestinal (GI) malignancies represent one of the most challenging scenarios for image-guided radiotherapy (IGRT). Despite technological advances, clinical practice remains heterogeneous among centres. This national, multidisciplinary Delphi consen...

Endovascular Thrombectomy for Cerebral Venous Thrombosis: Current Status and Future Directions

Abstract Cerebral venous thrombosis (CVT) represents a relatively rare cause of stroke, yet it carries an overall rate of death or dependency of up to 15%. The mainstay of its management is therapeutic anticoagulation, either subcutaneously or intravenously in the acute phase, fo...

Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice

Acoramidis, an oral transthyretin stabilizer that achieves near-complete stabilization, is approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on the phase 3 study, ATTRibute-CM (NCT03860935). To complement trial data, ACO-REAL (NCT07235462) was des...